Picture of ORIC Pharmaceuticals logo

ORIC — ORIC Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Oric Pharmaceuticals Inc reports results for the quarter ended in January - Earnings Summary

* Oric Pharmaceuticals Inc  ORIC.OQ  reported a quarterly
adjusted
loss of 37 cents​​ per share for the quarter ended in January,
higher than the same quarter last year, when the company
reported EPS of -53 cents.  The mean expectation of
nine analysts for the quarter was for a loss of 44 cents per
share. Wall Street expected results to range from -52 cents
to -39 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Oric Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 37 cents​.
    * The company reported a quarterly loss of $25.01 million.
    * Oric Pharmaceuticals Inc shares had fallen by 29.4% this
quarter and gained 5.5% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 16.2%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Oric
Pharmaceuticals Inc is $18.00 
This summary was machine generated from LSEG data May 6 at 11:49
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.44          -0.37          Beat
 Dec. 31 2023      -0.49          -0.49          Met
 Sep. 30 2023      -0.46          -0.44          Beat
 Jun. 30 2023      -0.57          -0.50          Beat

Recent news on ORIC Pharmaceuticals

See all news